Corcept Therapeutics Inc (NASDAQ: CORT) has experienced a decline in its stock price by -1.71 compared to its previous closing price of 48.06. However, the company has seen a gain of 0.15% in its stock price over the last five trading days. zacks.com reported 2024-10-23 that It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. JD, SKWD, CORT & PRA are well-poised to gain.
Is It Worth Investing in Corcept Therapeutics Inc (NASDAQ: CORT) Right Now?
Corcept Therapeutics Inc (NASDAQ: CORT) has a higher price-to-earnings ratio of 41.90x compared to its average ratio, The 36-month beta value for CORT is at 0.46. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CORT is 89.95M, and currently, shorts hold a 23.92% of that float. The average trading volume for CORT on October 25, 2024 was 906.25K shares.
CORT’s Market Performance
CORT stock saw an increase of 0.15% in the past week, with a monthly gain of 11.05% and a quarterly increase of 32.70%. The volatility ratio for the week is 3.62%, and the volatility levels for the last 30 days are 3.87% for Corcept Therapeutics Inc (CORT).. The simple moving average for the past 20 days is 1.59% for CORT’s stock, with a 54.15% simple moving average for the past 200 days.
Analysts’ Opinion of CORT
Many brokerage firms have already submitted their reports for CORT stocks, with Truist repeating the rating for CORT by listing it as a “Buy.” The predicted price for CORT in the upcoming period, according to Truist is $38 based on the research report published on November 06, 2023 of the previous year 2023.
SVB Securities, on the other hand, stated in their research note that they expect to see CORT reach a price target of $25. The rating they have provided for CORT stocks is “Market Perform” according to the report published on April 11th, 2023.
Piper Sandler gave a rating of “Overweight” to CORT, setting the target price at $27 in the report published on April 04th of the previous year.
CORT Trading at 15.86% from the 50-Day Moving Average
After a stumble in the market that brought CORT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.65% of loss for the given period.
Volatility was left at 3.87%, however, over the last 30 days, the volatility rate increased by 3.62%, as shares surge +9.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +39.80% upper at present.
During the last 5 trading sessions, CORT rose by +0.15%, which changed the moving average for the period of 200-days by +88.21% in comparison to the 20-day moving average, which settled at $46.50. In addition, Corcept Therapeutics Inc saw 45.44% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CORT starting from Guyer William, who sale 10,000 shares at the price of $46.28 back on Oct 01 ’24. After this action, Guyer William now owns 5,796 shares of Corcept Therapeutics Inc, valued at $462,800 using the latest closing price.
Robb Gary Charles, the Chief Business Officer of Corcept Therapeutics Inc, sale 11,000 shares at $46.28 during a trade that took place back on Oct 01 ’24, which means that Robb Gary Charles is holding 22,772 shares at $509,080 based on the most recent closing price.
Stock Fundamentals for CORT
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.98 for the gross margin
The net margin for Corcept Therapeutics Inc stands at 0.22. The total capital return value is set at 0.21. Equity return is now at value 24.55, with 20.17 for asset returns.
Based on Corcept Therapeutics Inc (CORT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 21.83. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 35.73.
Currently, EBITDA for the company is 109.64 million with net debt to EBITDA at -0.95. When we switch over and look at the enterprise to sales, we see a ratio of 8.45. The receivables turnover for the company is 10.15for trailing twelve months and the total asset turnover is 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.57.
Conclusion
In conclusion, Corcept Therapeutics Inc (CORT) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
